Current trends in the treatment of central venous thrombosis.
D000925:Anticoagulants / Q000627:therapeutic use; D005032:Ethylestrenol / Q000009:adverse effects / Q000627:therapeutic use; D005128:Eye Diseases / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000150:complications; D007989:Libido; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010629:Phenformin / Q000009:adverse effects / Q000627:therapeutic use; D012171:Retinal Vessels; D013924:Thrombophlebitis / Q000188:drug therapy*; D014688:Venoms / Q000627:therapeutic use; D014792:Visual Acuity; D014839:Vomiting / Q000139:chemically induced
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014688:Venoms; D005032:Ethylestrenol; D010629:Phenformin